1

Discovering Basic ScienceThe Weizmann Institute of Science

2

THE WEIZMANN INSTITUTE OF SCIENCE FOCUSED ON RESEARCH

260Professors

Heading research groups

400Administrative

staff

850Scientists

Ph.D.’s, engineers & technicians

1000Students

M.Sc. and Ph.D. only

3

THE WEIZMANN INSTITUTE OF SCIENCE FIVE FACULTIES

Mathematics

Computer Science

Chemistry Biology

Physics Biochemistry

The focus of scientists is

excellence inBasic Science

4

THE WEIZMANN INSTITUTE OF SCIENCELEIDEN RANKING

5

YEDA INDUSTRY IMPACT

80 companiesEstablished around Yeda’s

technologies

200 productsWith “Weizmann-Inside” technology

on the market

2070 patent families Filed since 1971

$22 billionAnnual WIS product sales

Yeda is the commercialization company with the highest income per researcher worldwide

Over 160 patent disclosures weresubmitted by WIS scientistsbetween 2013-2014

6

LICENSING INCOME SURVEY 2012 TOP 10 UNIVERSITIES *

Institution Licensing Income ($M)

1City of Hope National Medical Center. & Beckman Research

224

2 NYU 184

3 Columbia Univ. 161

4 Sloan Kettering Inst. For Cancer Res. 143

5Massachusetts Institute ofTechnology (MIT)

137

6 Princeton University 130

7 Northwestern University 122

8 Univ. California System 102

9The General Hospital dbaMassachusetts General Hos.

99

10 University of Washington 77

* Source: AUTM Licensing Survey 2012

7

$4,027M

$2,434M

COPAXONE

Rebif

COPAXONE and Rebif are two blockbuster treatments for multiple sclerosis developed at the Weizmann institute

SUCCESS STORIES MULTIPLE SCLEROSIS TREATMENT

$2,912MAVONEX

Other

Weizmann

8

FROM A SINGLE PATENT TO THREE DRUGS

$1,081 MILLIONErbitux® Merck and Eli Lillymetastatic colorectal cancer

$359 MILLIONVectibix® AMGENColorectal cancer

$500 M (EST 2016)Portrazza® Eli LillyLung cancer

Prof. Sela and colleagues discovered that EGFR-inhibiting antibodies produce a synergistic anticancer effect when used together with chemotherapy

The three EGFR blockers are saving the lives of hundreds of thousands of cancer patients all over the world

EGFR blockers

9

AbbVie’s leading product, responsible for up to 57% of its overall sales

Worldwide sales: $12.54 billion in 2014

HUMIRA® was the first fully human monoclonal antibody drug approved by the FDA

It was ranked the best selling drug worldwide in 2013

SUCCESS STORIES HUMIRA

10

TOOKAD®Targeted photodynamic

therapy

A result of collaboration between the Weizmann Institute and Steba biotech

Recently approved therapy for prostate cancer in Mexico and in Israel

European Phase III clinical trial is currently under evaluation by the EMA

TOOKAD® Soluble VTP is a day-case procedure lasting approximately 90 minutes. This new minimally invasive technology offers a good alternative to patients diagnosed with early-stage prostate cancer

Prof. Avigdor Scherz and Prof. Yoram Salomon

11

WORLD LEADING SCIENTISTS

PROF. ADA YONATH

• The pioneer of ribosome crystallography

• Nobel Laureate in Chemistry, 2009

• The first Israeli woman to win the NobelPrize out of ten Israeli Nobel laureates

PROF. ZELIG ESHHAR

Developed the first CAR T-cells

(novel strategy for cancer treatment with promising results and multi-billion dollar market )

12

TURING AWARD LAUREATES

PROF. ADI SHAMIR

A world leading cryptographer

co-inventor of the RSA algorithm for secure data transmission

PROF. AMIR PNUELI

Received the Turing Award in 1996 for seminal work introducing temporal logic into computing science and for outstanding contributions to program and systems verification

PROF. SHAFI GOLDWASSER

Her work on laid the rigorous foundations for modern cryptography and pioneered several themes which are today considered basic to the field

13

INTERDISCIPLINARY INNOVATION

Dr. Eran Elinav

A new start-up based on

Weizmann science

Prof. Eran Segal

Host-microbiome interactions and their effects on health

and disease

Computer Science and Applied Mathematics

Personalized nutrition based on gut microbiome

14

Yeda has a diverseportfolio whichcovers a broadspectrum of thepharmaceutical andbiotech industry

THE CURRENT TECHNOLOGY PIPELINE

Drug Targets Small molecules Antibodies

Diagnostics Research toolsMedical Device

15

TO MAKE THE NEXT SCIENTIFIC BREAKTHROUGH

PARTNER WITH US